Some members of the CIS/SOCS/JAB/SSI family have been demonstrated to be cytokine-inducible inhibitors of cytokine signaling. Steps have now been made towards clarifying the biological function of two of these proteins, revealing that these inhibitors are essential for the correct maintenance of cytokine signaling.
Most mammalian cell types express a wide variety of cytokine receptors at the cell surface. These receptors translate and transduce various signals from the external environment to the interior of the cell to generate the appropriate response. The last five years have been a period of remarkable progress in elucidating the biochemistry of cytokine signaling. The discovery and characterization of Janus kinases (JAKs) that bind to cytokine receptors and phosphorylate signal transducers and activators of transcription (STATs) has been of particular importance. The JAK-STAT pathway is an integral component of signaling by many cytokines. Significant progress has also been made in understanding the importance of the correct regulation of this signaling pathway. In addition to the role of phosphatases, such as Shp1 and Shp2 [1] , in the downregulation of cytokine signaling, a considerable amount of attention has been focused on a set of proteins that include cytokineinducible signaling inhibitors. This family of proteins was last reviewed in Current Biology in 1997 [2] . Since then, significant new information regarding the specific roles of certain members of this family of inhibitors has been gained from studies on transgenic and knockout mice [3] [4] [5] [6] [7] [8] .
The prototype member of this family, cloned back in 1995 [9] , was denoted CIS, for cytokine-inducible Src homology 2 (SH2)-domain-containing protein. This protein was identified as an immediate-early gene whose expression was induced by interleukin-2 (IL-2), IL-3, and erythropoietin. CIS (now also denoted as CIS1) was demonstrated initially to associate with the erythropoietin receptor and the β chain of the IL-3 receptor [9] . It has subsequently been shown to also be able to associate with the common β chain, β c , of the receptors for IL-3, IL-5, and granulocyte-macrophage colony-stimulating factor (GM-CSF), and the IL-2 receptor β chain [10] . CIS1 can negatively regulate signaling by these cytokines in cell lines [9, 10] as well as in transgenic mice [8] . Interestingly, expression of the CIS1 gene is regulated by Stat5 proteins, which themselves are activated by IL-2, IL-3, and erythropoietin. Thus, CIS1 appears to represent a component of a negative-feedback loop in cytokine signaling.
Two years ago, three groups used different experimental approaches to clone a cytokine-inducible protein that inhibited the actions of IL-6 and leukemia inhibitory factor [11] [12] [13] . This new protein was variably denoted as SOCS-1 (suppressor of cytokine signaling-1), JAB (JAK-binding protein), or SSI-1 (STAT-induced STAT-inhibitor-1) proteins. Two other structurally related proteins were also identified (SOCS-2 and SOCS-3) at the same time. Like CIS1, all three of these proteins contain an SH2 domain as well as other regions of homology [2] . Thus, the CIS/SOCS/JAB/SSI family was recognized to exist [2] . The nomenclature for this family of proteins was then, and still is, confusing. In addition to the SOCS nomenclature (where the hyphen has now been lost so that SOCS-1 is denoted as SOCS1), the CIS, JAB, and SSI-1 nomenclatures are still used.
In reality, none of the names is necessarily completely appropriate. Firstly, a range of proteins have been identified to have homology to a carboxy-terminal motif of CIS/SOCS1/JAB/SSI-1, termed the SOCS box. Although some of these proteins contain SH2 domains, others instead contain WD40 repeats, SPRY domains, ankyrin repeats or GTPase domains (Table 1 ) [14] . Thus, the CIS nomenclature does not accurately encompass all of these proteins; moreover, not all of these proteins have been shown to be cytokine inducible. Secondly, it is not yet clear whether all of these proteins suppress cytokine signaling or whether all are STAT inhibitors; therefore, the SOCS and SSI nomenclature may not be completely appropriate either. Finally, although JAB associates with JAKs, CIS1 does not, so the ability to interact with JAKs is also not a universal feature of these proteins. For the purpose of this article, however, we will focus only on those proteins that contain a central SH2 domain and a carboxy-terminal SOCS box (see Table 1 ).
As noted above, since their cloning the CIS/SOCS/JAB/SSI proteins have been linked to the negative regulation of a number of cytokines. Some of these proteins, such as SOCS1/JAB/SSI-1, SOCS3/CIS3/SSI-3, and CIS1, are induced by many different cytokines [2] , and their induction seems to be dependent on STATs. The mechanism by which these proteins inhibit cytokine signaling is not fully understood. SOCS1/JAB/SSI-1 and SOCS3/CIS3/SSI-3 associate with JAKs and inhibit their activity, thus providing a possible explanation for their inhibitory action [15, 16] . In contrast, CIS1 associates with receptors but does not bind JAKs. Figure 1 depicts SOCS1/JAB/SSI-1 associating with JAKs and CIS1 with cytokine receptor chains. The CIS1 SH2 domain is essential for the inhibitory action of CIS1, but the protein(s) that interacts with this domain remains unclear [10] . For SOCS1/JAB/SSI-1, the region amino-terminal to the SH2 domain is clearly required for efficient binding to JAKs and for the function of the protein [15, 17, 18] . The function of the SOCS box is currently not known, although it does not appear to be required for inhibition of Jak2 activity by SOCS1/JAB/SSI-1 and instead may regulate the stability of the protein [17, 19, 20] . This putative function of the SOCS box involves an interaction with elongins B and C, but it has not yet been resolved whether this interaction results in increased or decreased protein stability [19, 20] .
Most of the data linking CIS/SOCS/JAB/SSI proteins to the negative regulation of cytokine signaling have been obtained from overexpression models. Although these systems provide valuable information, they cannot provide a clear understanding of whether a given protein is required for a biological action in vivo. The initial analysis of mice deficient in SOCS1/JAB/SSI-1, which we shall term SOCS1 in the remainder of the review, revealed an essential role for SOCS1 in vivo [3, 4] . Mice lacking SOCS1 exhibited post-natal death that was associated with growth retardation, liver degeneration and necrosis, and lymphoid abnormalities that included diminished cellularity of the thymus and loss of B lymphocytes. This phenotype was surprising, because it was not clearly attributable to an amplified cytokine response, as one might have expected. In addition, these mice showed no signs of generalized inflammation, which might have been expected, given that this phenotype is observed in mice deficient in Shp1 [21] , a phosphatase that also inhibits the action of certain cytokines.
The changes observed in SOCS1-deficient mice may have been caused by the loss of a function(s) of SOCS1 that is not necessarily directly related to augmented cytokine signaling, but instead might relate to effects on apoptosis. In fact, lymphocytes from these mice were observed to have a significantly accelerated rate of apoptosis that correlated with increased expression of the pro-apoptotic Bcl-2-family member Bax [3] . Nevertheless, it was clear that cytokine signaling in SOCS1 knockout mice was also abnormal, because thymocytes from the mice were hyper-responsive to the combination of triggering of the T-cell receptor and treatment with IL-2 or IL-4, indicating that the responsiveness of T cells to at least these cytokines was altered [3] . Consistent with this observation, constitutive Stat1 activity was observed in the liver tissue of SOCS1-deficient mice [4] , suggesting enhanced signaling by cytokines that activate Stat1, such as interferon γ (IFNγ) or IL-6. Other proteins containing the SOCS box motif but which do not contain an SH2 domain have been described and are detailed in [14] . These include proteins containing SPRY domains, SSB-1, SSB-2, SSB-3; those containing GTPase domains, retinoic acid receptor (RAR), RAR-LIKE; those containing WD40 repeats, WSB-1, WSB-2; and those containing ankyrin repeats, ASB-1, ASB-2, ASB-3. LIF, leukemia inhibitory factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; G-CSF, granulocyte colony-stimulating factor; M-CSF, macrophage colony-stimulating factor; EPO, erythropoietin; TPO, thrombopoietin; SCF, stem cell factor; TNFα, tumor necrosis factor α.
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In a recent issue of Cell, two reports [5, 6] have clarified several of the issues raised by the original reports describing SOCS1-deficient mice. Both studies demonstrate that the major phenotypic abnormalities observed in these mice are, in fact, caused by alterations in cytokine signaling. In particular, these papers reveal that IFNγ is an essential mediator of the pathological changes in the mice. Interestingly, in neonatal mice, injections of IFNγ induce pathological changes similar to those observed in SOCS1 knockout mice [22] . Moreover, constitutive expression of IFNγ in transgenic mice causes hematological and immunological changes similar to those observed in mice deficient in SOCS1, with B cells being particularly sensitive to the toxic effects of IFNγ [23, 24] .
Other studies have shown not only that IFNγ can induce SOCS1 expression, but also that SOCS1 can inhibit IFNγ signaling [5, 25, 26] , suggesting that SOCS1 is part of a negative-feedback loop regulating IFNγ signaling. Indeed, whereas IFNγ injections in neonatal mice cause similar pathological effects to those seen in SOCS1-deficient mice, administration of a neutralizing anti-IFNγ antibody to these mice prevents these pathological changes [5] . Furthermore, the mice are highly resistant to infection with Semliki forest virus, an anti-viral response that is dependent on IFNγ activity. In addition, SOCS1-deficient mice show a more than 100-fold increase in the level of IFNγ-dependent killing of Leishmania major by macrophages. Finally, mice deficient in both SOCS1 and IFNγ do not exhibit the multi-organ pathology seen in mice deficient in SOCS1 alone, thus proving the essential role of IFNγ in mediating toxicity in SOCS1-deficient mice.
Because activated T cells are rich sources of IFNγ, the effects of the lack of SOCS1 expression were also analyzed in mice that do not produce T or B lymphocytes due to the absence of the recombination-activating gene RAG2 [6] . Interestingly, the resulting mice do not exhibit the phenotypic abnormalities seen in mice that lack SOCS1 expression alone, indicating that the pathological changes are mediated by lymphocytes, presumably T lymphocytes, because B lymphocytes do not produce significant amounts of IFNγ. Similar observations are made when the hematopoietic system of Jak3-deficient mice, which are significantly deficient in all lymphoid cells, is reconstituted with bone marrow from SOCS1-deficient mice.
Together, these results demonstrate that lymphocytes are required for the abnormalities seen in SOCS1 knockout mice, at least in part because of their production of IFNγ.
What might be the cause of this excessive IFNγ production? One possibility is that T-lymphocyte function in general is abnormal in these mice. This is supported by the finding that peripheral T cells from these mice exhibit an 'activated' phenotype [6] , a finding consistent with the hyper-responsiveness of these cells to IL-2 and IL-4 [3] .
Thus, the absence of SOCS1 may lead to amplified responses to a number of cytokines. This, in turn, may result in aberrant T-lymphocyte activation and abnormal IFNγ production, finally culminating in the observed pathological effects.
The role of SOCS3 in vivo has also been analyzed. Mice expressing a SOCS3 transgene as well as mice deficient in SOCS3 have been generated and the analysis of these mice revealed that SOCS3 expression is essential for regulating fetal erythropoiesis [7] . SOCS3 overexpression completely blocks fetal erythropoiesis, whereas SOCS3-deficient embryos show increased erythrocytosis, and neither SOCS3 transgenic or knockout embryos are viable. A temporal comparison of SOCS3 expression and fetal erythropoiesis is consistent with negative regulation of erythropoietin signaling by SOCS3. In support of this, the phenotype of SOCS3 transgenic mice closely resembles that of mice lacking expression of Jak2 or the erythropoietin receptor [27] [28] [29] . It is noteworthy that the expression of SOCS1 and SOCS3 seems to be developmentally regulated. It will be most Dispatch R901 interesting to clarify the mechanism behind the coordinated expression of SOCS proteins, as well as the precise roles of these proteins during development.
Thus, although CIS/SOCS/JAB/SSI proteins were recognized as inhibitors of cytokine signaling back in 1997, at that stage the field was in its infancy in terms of understanding which of these inhibitors was most important for which particular cytokines. Although much remains to be learned, the murine models have now clarified our understanding of the essential roles for SOCS1 and SOCS3 in vivo.
